Chapel Hill, NC, United States of America

Huaxin Sheng

This inventor holds 1 USPTO granted patent and 3 published patent applications. Top assignee: Duke University. Active years: 2015.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2015

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Huaxin Sheng: Innovator in Cancer Research

Introduction

Huaxin Sheng is a prominent inventor based in Chapel Hill, NC (US). He has made significant contributions to the field of cancer research, particularly through his innovative patent related to cancer therapy. His work focuses on understanding and targeting cancer cell proliferation, which is crucial for developing effective treatments.

Latest Patents

Huaxin Sheng holds a patent titled "SUMO as a marker of cancer development and target for cancer therapy." This patent discloses methods for inhibiting or reducing the proliferation of cancer cells. It also outlines approaches for predicting the risk of cancer progression and screening for cancer in subjects. The methods involve detecting and/or decreasing the levels of SUMO conjugated proteins and interfering with SUMO conjugation.

Career Highlights

Huaxin Sheng is affiliated with Duke University, where he conducts his research. His work has garnered attention for its potential impact on cancer treatment and patient outcomes. With a focus on innovative methodologies, he continues to advance the understanding of cancer biology.

Collaborations

Some of Huaxin Sheng's notable coworkers include Wulf Paschen and Wei Yang. Their collaborative efforts contribute to the ongoing research and development in the field of cancer therapy.

Conclusion

Huaxin Sheng's contributions to cancer research through his patent and work at Duke University highlight his role as an innovator in the medical field. His research has the potential to significantly influence cancer treatment strategies and improve patient care.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…